Cancer Archives

News and Trends 15 Jun 2022

TILT Biotherapeutics raises $10M to push ahead on cancer immunotherapies

TILT Biotherapeutics (TILT), a clinical-stage Finnish biotech company developing cancer immunotherapies, has completed the first close of its financing round, raising $10.7 million. It was led by Lifeline Ventures and joined by Tesi (Finnish Industry Investment Ltd). The funding will be used to advance phase I/II programs in Europe and the U.S., using TILT-123 plus […]

June 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 9 Jun 2022

Amaroq Therapeutics ‘hits early milestones’ in cancer treatment

New Zealand biotech company Amaroq Therapeutics said it is progressing towards clinical trials following a promising initial development phase. The company, a start-up spun out of the University of Otago, is focused on developing a new class of therapeutics that target long non-coding RNAs (lncRNA) in cancer. Sarah Diermeier, chief scientific officer and founder of […]

June 9, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 8 Jun 2022

Neuroendocrine cancer under the spotlight as Ariceum Therapeutics launches

Ariceum Therapeutics, a private biotech company developing a radiopharmaceutical product for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, has completed an oversubscribed €25M ($26.7M) Series A financing round. Ariceum was co-founded by EQT Life Sciences (formerly LSP) and HealthCap, which also co-led the financing that was joined by Pureos Bioventures. Ipsen […]

June 8, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 7 Jun 2022

Cancer vaccine biotech CimCure raises €5M

Dutch biotech company CimCure, which is focusing on the development of vaccine-based cancer immunotherapy, has raised more than €5M ($5.3M) in a financing seed round led by Dutch company Positron Ventures. CimCure, a spin-off of the Amsterdam UMC medical center, is set to use the funds to advance its vaccine up to phase 1-2 clinical […]

June 7, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 7 Jun 2022

ImmunOs Therapeutics raises $74M

ImmunOs Therapeutics AG, a biopharmaceutical company developing therapeutics for the treatment of cancer and autoimmune diseases, has announced the closing of an oversubscribed Series B financing round totaling $74M. The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by other new investors Mission BioCapital, GL Capital, PEAK6 Strategic […]

June 7, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 31 May 2022

ANGLE and U.S. urology group to undertake prostate cancer study

ANGLE plc has signed a master clinical study agreement with Solaris Health Holdings, LLC and joinder agreements with MidLantic Urology LLC, to collaborate and conduct clinical studies in prostate cancer and as a potential route to market in the U.S. Alongside Solaris affiliate MidLantic Urology, UK-headquartered ANGLE will initiate clinical studies aimed at detecting prostate […]

May 31, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 27 May 2022

HotSpot looks to boost cancer therapy pipeline with Excelra partnership

U.S. biotech company HotSpot Therapeutics, Inc. is looking to increase its drug development and discovery efforts by partnering with Indian data and digital insights company Excelra. HotSpot discovers and develops small molecule allosteric therapies for the treatment of cancer and autoimmune diseases. What are allosteric therapies? In the journal ACS Medicinal Chemistry Letters, Ahmed F. […]

May 27, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 27 May 2022

Companies partner on early lung cancer detection blood test

U.S. company CorePath Laboratories is partnering with U.K. diagnostics firm Cizzle Biotechnology on an early-stage lung cancer test for the U.S. Lung cancer is the leading cause of cancer deaths in the U.S., making up almost 25% of all cancer deaths. Each year, more people die of lung cancer than of colon, breast, and prostate […]

May 27, 2022 - 3 minutesmins - By Jim Cornall

cancer dna damage repair duke street bio parp

News and Trends 25 May 2022

Duke Street Bio enters stage with next-generation cancer therapies

The UK startup Duke Street Bio has exited stealth mode with funding to develop PARP enzyme inhibitors that treat cancer by blocking the repair of DNA in tumor cells. London-based Duke Street Bio said Tuesday that it has a portfolio of PARP1 and PARP7 enzyme inhibitors and has raised enough cash to fund its pipeline […]

May 25, 2022 - 3 minutesmins - By Susannah Rodgers

News and Trends 13 May 2022

Domain Therapeutics Bags €39M to Block GPCRs in Cancer Immunotherapy

Domain Therapeutics, a biopharmaceutical company in France and Canada developing cancer immunotherapies targeting G protein-coupled receptors (GPCRs), has closed a €39M ($42M) Series A financing round to move its lead candidate to clinical trials. The approval of the first immune checkpoint inhibitor treatments in 2014 proved a gamechanger for cancer immunotherapy as they prevented tumors […]

May 13, 2022 - 4 minutesmins - By Jim Cornall

In Depth 9 May 2022

Exosome Therapy: Borrowing from Nature’s Toolbox

In just a few years, exosomes have started gaining recognition as a solution to deliver treatments safely and effectively, and as a new approach to regenerative medicine. For hundreds of millions of years, multicellular organisms have faced many of the same challenges that biotechnology is grappling with today: how best to shuttle biomolecules to and […]

May 9, 2022 - 11 minutesmins - By Farhan Mitha

News and Trends 5 May 2022

Amphista Lands Megadeals to Smash Cancer using Protein Degradation

As big pharma companies flock to drugs that destroy harmful proteins, the UK protein degradation specialist Amphista Therapeutics has bagged two landmark collaboration deals with the heavyweights Bristol Myers Squibb and Merck. Big pharma companies are piling onto biotechs developing drugs that can cause the destruction of target proteins in the cell — a field […]

May 5, 2022 - 3 minutesmins - By Jonathan Smith

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

TILT Biotherapeutics raises $10M to push ahead on cancer immunotherapies

Amaroq Therapeutics ‘hits early milestones’ in cancer treatment

Neuroendocrine cancer under the spotlight as Ariceum Therapeutics launches

Cancer vaccine biotech CimCure raises €5M

ImmunOs Therapeutics raises $74M

ANGLE and U.S. urology group to undertake prostate cancer study

HotSpot looks to boost cancer therapy pipeline with Excelra partnership

Companies partner on early lung cancer detection blood test

Duke Street Bio enters stage with next-generation cancer therapies

Domain Therapeutics Bags €39M to Block GPCRs in Cancer Immunotherapy

Exosome Therapy: Borrowing from Nature’s Toolbox

Amphista Lands Megadeals to Smash Cancer using Protein Degradation

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!